Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...

New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...

New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...